These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 28621801)

  • 21. Markers of coagulation activation and enhanced fibrinolysis in Gaucher type 1 patient: Effects of enzyme replacement therapy.
    Mitrovic M; Sumarac Z; Antic D; Bogdanovic A; Elezovic I; Vukosavljevic D; Ignjatovic S; Majkic-Singh N; Suvajdzic N
    Blood Cells Mol Dis; 2012 Jun; 49(1):58-9. PubMed ID: 22459893
    [No Abstract]   [Full Text] [Related]  

  • 22. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D; Altarescu G; Maayan H; Phillips M; Abrahamov A; Hadas-Halpern I; Tiomkin M; Zimran A
    Blood Cells Mol Dis; 2012 Jan; 48(1):45-50. PubMed ID: 22047948
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Retinal Deposits in a Young Woman.
    Oliver R; Sallam AB; Uwaydat SH
    JAMA Ophthalmol; 2018 Jun; 136(6):708-709. PubMed ID: 29522126
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment-naïve Gaucher disease patients achieve therapeutic goals and normalization with velaglucerase alfa by 4years in phase 3 trials.
    Zimran A; Elstein D; Gonzalez DE; Lukina EA; Qin Y; Dinh Q; Turkia HB
    Blood Cells Mol Dis; 2018 Feb; 68():153-159. PubMed ID: 27839979
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of switching from imiglucerase to velaglucerase alfa without dose reduction nor wash out in type 1 Gaucher disease.
    Serratrice C; Bengherbia M; Alessandrini M; Grosbois B; Camou F; Pers YM; Bismuth M; Marie I; Belmatoug N; Berger M;
    Blood Cells Mol Dis; 2014; 53(1-2):94-6. PubMed ID: 24411065
    [No Abstract]   [Full Text] [Related]  

  • 26. Taliglucerase alfa in Gaucher disease: Description of a Brazilian experience.
    Cravo R; Rotman V; Oliveira PMN; Defendi HGT; Conceição DA; Xavier JR; Chertkoff R; Noronha TG; Maia MLS
    Blood Cells Mol Dis; 2018 Feb; 68():160-162. PubMed ID: 28131618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease.
    Pastores GM
    Curr Opin Investig Drugs; 2010 Apr; 11(4):472-8. PubMed ID: 20336596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enzyme replacement therapy in a child with Gaucher disease.
    Masood Y; Ali AS
    J Coll Physicians Surg Pak; 2006 Dec; 16(12):786-8. PubMed ID: 17125641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Shankar SP; Petakov M; Giraldo P; Rosenbaum H; Amato DJ; Szer J; Chertkoff R; Brill-Almon E; Zimran A
    Am J Hematol; 2016 Jul; 91(7):661-5. PubMed ID: 27102949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up.
    Elstein D; Haims AH; Zahrieh D; Cohn GM; Zimran A
    Blood Cells Mol Dis; 2014; 53(1-2):56-60. PubMed ID: 24581483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
    Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
    Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validating glycoprotein non-metastatic melanoma B (gpNMB, osteoactivin), a new biomarker of Gaucher disease.
    Murugesan V; Liu J; Yang R; Lin H; Lischuk A; Pastores G; Zhang X; Chuang WL; Mistry PK
    Blood Cells Mol Dis; 2018 Feb; 68():47-53. PubMed ID: 28003098
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease.
    Arıkan-Ayyıldız Z; Yuce A; Uslu-Kızılkan N; Demir H; Gurakan F
    Pediatr Blood Cancer; 2011 Apr; 56(4):664-6. PubMed ID: 21298757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidative stress, trace elements, and circulating microparticles in patients with Gaucher disease before and after enzyme replacement therapy.
    Zahran AM; Elsayh KI; El-Deek SE; El-Baz MA
    Clin Appl Thromb Hemost; 2015 Jan; 21(1):58-65. PubMed ID: 23698728
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention.
    Boot RG; Verhoek M; de Fost M; Hollak CE; Maas M; Bleijlevens B; van Breemen MJ; van Meurs M; Boven LA; Laman JD; Moran MT; Cox TM; Aerts JM
    Blood; 2004 Jan; 103(1):33-9. PubMed ID: 12969956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucosylsphingosine (lyso-Gb1) as a Biomarker for Monitoring Treated and Untreated Children with Gaucher Disease.
    Hurvitz N; Dinur T; Becker-Cohen M; Cozma C; Hovakimyan M; Oppermann S; Demuth L; Rolfs A; Abramov A; Zimran A; Revel-Vilk S
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234327
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM; Petakov M; Giraldo P; Rosenbaum H; Szer J; Deegan PB; Amato DJ; Mengel E; Tan ES; Chertkoff R; Brill-Almon E; Zimran A
    Blood Cells Mol Dis; 2014 Dec; 53(4):253-60. PubMed ID: 24950666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current development and usefulness of biomarkers for Gaucher disease follow up].
    Maire I; Guffon N; Froissart R
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S187-92. PubMed ID: 18228687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment patterns from 647 patients with Gaucher disease: An analysis from the Gaucher Outcome Survey.
    Deegan P; Fernandez-Sasso D; Giraldo P; Lau H; Panahloo Z; Zimran A
    Blood Cells Mol Dis; 2018 Feb; 68():218-225. PubMed ID: 27829541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.